Trailhead Biosystems Raises $20M in Funding for Human Cell Innovation
Trailhead Biosystems, a biotechnology company based in Beachwood, OH, has secured $20 million in funding for its innovative work with human cells.
The company plans to utilize the investment to expand its range of iPSC-derived cells for various research purposes, including advancing preclinical drug discovery and disease modeling.
CEO, CSO, and Founder Jan Jensen leads Trailhead Biosystems, which utilizes a unique high-dimensional design of experiments (HD-DoE®) platform to differentiate induced pluripotent stem cells (iPSCs) into functional human cell types for regenerative medicine and drug discovery.
One of the recent introductions by Trailhead Biosystems is the TrailBio® Vascular Leptomeningeal Cells (VLMCs), specifically designed for blood-brain barrier research to address critical needs in neuroscience and drug delivery.
In addition to its headquarters in Beachwood, the company also operates an office in Kendall Square, Cambridge, MA.
FinSMEs
10/05/2025
